TO THE EDITOR,
Chronic neutrophilic leukemia (CNL) is a rare chronic myeloproliferative disorder (CMPD) with only B150 cases reported to date, which has only recently attained formal recognition as a distinct entity within the updated World Health Organization (WHO) classification system. 1, 2 CNL is characterized by sustained, mature neutrophilic leukocytosis with few or no circulating immature granulocytes, monocytosis or basophilia. Affected patients usually display splenomegaly and bone marrow (BM) histology reveals granulocytic hyperplasia without evidence of dysplasia or striking reticulin fibrosis. Cytogenetic and molecular analyses are negative for the Philadelphia chromosome (Ph chromosome) and/or its molecular counterpart, fusion of bcr and abl genes (b2/a2, b3/a2 or e19/a2 junction). The diagnosis is contingent upon thorough initial investigation and follow-up to exclude the underlying causes of reactive neutrophilia, particularly if evidence of myeloid clonality is lacking. In addition, features of other CMPD, chronic myelogenous leukemia (CML), atypical CML (aCML), and chronic myelomonocytic leukemia (CMML), as defined by the WHO, must be absent. 2 Furthermore, CNL should be differentiated from neutrophilic-CML (CML-N), which is a rare variant of bcr/abl (e19/a2 junction)-driven Ph-positive CML.
Previously, we reported six cases of CNL in your Journal in 2001 3 and wish to update our original series by providing longterm follow-up, and reporting six additional cases. Of significance, since our earlier publication, the WHO classification has provided stringent diagnostic criteria, enabling a uniform system to ensure the correct diagnosis of this rare CMPD. We recently critically reviewed the literature for previously reported cases. 4 From this review, it became apparent that many cases did not meet the current WHO criteria (Table 1) , and cannot be confirmed to be 'true' cases of CNL. We here summarize our single-institution experience of 12 CNL cases and review earlierpublished cases meeting the new WHO diagnostic criteria.
Clinical records from 12 consecutive patients with features consistent with CNL, evaluated at our institution from 1992 to 2003, were reviewed with Institutional Review Board approval (Table 2) . Standard cytogenetic analysis was complimented with fluorescent in situ hybridization (FISH) to detect fusion of bcr and abl that results from all forms of the Ph chromosome. 5 By definition, each of these patients had a mature neutrophilic leukocytosis. No blasts were seen and no dysplastic features were noted in the granulocytic series. No absolute or relative monocytosis, eosinophilia, or basophilia was identified. The leukocyte alkaline phosphatase (LAP) score (normal range: 40-100) was elevated in the majority (8/9) in whom it was tested and low in one patient who had a score of 9 (median LAP score of group: 266, range ¼ 9-394). None of the patients had any significant co-morbidities, such as infection, malignancy or systemic inflammatory disease, capable of causing a reactive neutrophilia or leukemoid reaction. The BM biopsies were uniformly hypercellular (490%) due to marked granulocytic hyperplasia. Reticulin stain showed at most 1 þ reticulin fibrosis (on a 0-4 scale). In all, 10 of the 12 (83%) patients had normal cytogenetics at diagnosis (Table 2) . Neither a Ph chromosome nor fusion of bcr and abl was observed in any of these patients. All patients had follow-up chromosome analysis performed one or more times after the baseline study. An abnormal cytogenetic clone appeared to develop during the course of the disease in three patients who had been cytogenetically normal at baseline, at 15 (trisomy 21), 23 (del12p), and 19 (monosomy 7 at the time of myeloid blast transformation) months following the diagnosis of CNL, respectively. All of these patients had been treated with hydroxyurea alone for at least 12 months (range: 12-18) prior to detection of these karyotypic changes.
No underlying disease process as a cause of reactive leukocytosis became apparent during follow-up (median: 25.5 months, range: 3-106). In all, 11 patients (92%) received and responded initially to therapy with hydroxyurea with reduction of leukocytosis and splenomegaly. The median duration of hydroxyurea therapy was 12 months (range: 6-87) and two continue in chronic stable phase on this agent for 18 and 87 months. Three patients eventually became refractory to hydroxyurea, manifesting progressive neutrophilia without BT at 6, 12, and 13 months, with a maximal neutrophil count of 144.8, 145, and 244 Â 10 9 /l (cases 2, 5, and 3), respectively. Response to subsequent therapy, including low-dose cytarabine, 6-thioguanine (6-TG), 2-chloro- Table 1 WHO diagnostic criteria for chronic neutrophilic leukemia Four patients discontinued hydroxyurea as a result of worsening transfusion-dependent anemia and thrombocytopenia, without similar decline in the neutrophilia and progressive splenomegaly. One (case 12) died shortly post-splenectomy (splenic pathology showed mature neutrophilic tissue infiltration), as a result of fulminant refractory post-splenectomy neutrophilia. Another (case 4) received splenic irradiation elsewhere, with symptomatic relief of splenomegaly but persistent transfusion-dependent anemia and thrombocytopenia, the latter ultimately resulting in fatal intracranial hemorrhage. One died shortly after discontinuation of hydroxyurea of PD and the other remained red cell and platelet transfusion dependent until BT. Myeloid BT developed in three patients at 19, 20, and 25 months. Two had a normal karyotype at BT (at ages 88 and 73), declined induction chemotherapy, and survival with supportive care was only 8 and 14 weeks, respectively. The third (case 8, age 49 at BT) acquired monosomy 7. The use of standard AML induction led to clearance of the BM blasts and reestablishment of a normal karyotype. However, the patient remained pancytopenic with a hypocellular BM up until allogenic HLAidentical sibling stem cell transplantation (SCT), succumbing to regimen-related toxicity on day 32. At the last follow-up, three patients remain alive in stable chronic phase on hydroxyurea (n ¼ 2) or with observation alone at 106, 78, and 25 months (cases 1, 10, and 9), respectively. Nine patients died at a median of 23.5 months from CNL diagnosis (range: 9-56). Cause of death include PD (n ¼ 4), cytopenic complications of treatment thereof (n ¼ 2), BT (n ¼ 2) or regimen-related toxicity of transplantation (n ¼ 1).
We have herein described our experience with the largest series of CNL with long-term follow-up meeting the current WHO diagnostic criteria. The literature was critically reviewed and a total of 28 additional patients meeting these criteria with adequate clinical information were identified and combined with our 12 cases for analysis (Table 2) . Cytogenetic abnormalities were reported in 13 out of 40 (32.5%) patients. These abnormal clones were detected at first assessment in eight out of 40 (20%) patients or arose as clonal evolution during follow-up in five out of 40 (12.5%). Most of the latter group had received interim cytoreductive therapy. Although the numbers are small, the occurrence of 20qÀ (n ¼ 3), 21 þ (n ¼ 3), 11qÀ (n ¼ 2) and 12pÀ (n ¼ 2) are recurrent within this limited data set and are all nonrandom findings in myeloid disorders. The majority had a normal karyotype. The primary genetic event that leads to CNL is most likely submicroscopic and the chromosome abnormalities reported likely represent secondary abnormalities. Clonality in CNL has also been established with other techniques, including progenitor cell assays, 6 X-inactivation patterns, and suggested by reduced susceptibility of malignant neutrophils to apoptosis. 7 By definition and in accord with the WHO diagnostic criteria, none of the patients included in this report had a Ph chromosome or bcr/abl fusion. Rarely, the breakpoint in BCR occurs in the mu region (m-BCR), resulting in e19/a2 junction, encoding a larger fusion protein (p230). Pane et al 8 described three patients with Phpositive CML with prominent neutrophilia and this variant translocation. The term neutrophilic-CML (CML-N) was coined and it was hypothesized that this molecular abnormality may be the underlying marker in all cases of CNL. Thus far, subsequent cases of CNL examined have failed to confirm a cryptic p230 as the causative molecular event in CNL. 3, 9 Furthermore, all cases of CML with this e19/a2 junction thus far reported have had cytogenetic evidence of the Ph chromosome and many had a phenotype not consistent with CNL. 10 Like other CMPD, the clinical course of CNL is heterogeneous. Disease acceleration often manifests with the development of progressive neutrophilia with resistance to previously effective therapy, progressive splenomegaly or worsening thrombocytopenia (not related to therapy), or with cytogenetic clonal evolution. BT, which to date has been exclusively reported as myeloid, occurs in a significant proportion at a median of 21 months (range: 3-94) from diagnosis. No hematologic complete remission has been described to date following induction therapy for accelerated or blast phase in CNL. In our review, standard induction chemotherapy was successful at attaining a second CP in one patient only (case 18). In the remaining patients the leukemia was either refractory, the BM remained hypoplastic, death occurred during attempts at remission induction or palliative management was provided for patients not willing or able to receive induction chemotherapy. A similar situation has been observed among patients with refractory progressive neutrophilia. 3 Optimal therapy of CNL remains to be defined. Splenectomy has resulted in worsening of neutrophilic leukocytosis and cannot be recommended. Treatment of CNL to date has consisted largely of cytoreductive agents such as hydroxyurea. In the cases reviewed, this was the first-line agent most often employed (80% of cases) and approximately 75% had a clinical response in terms of decrease in leukocytosis and/or splenomegaly. Responses were maintained for a median of 12 months (range: 1-87 plus), until there was evidence of disease acceleration or BT. However, some cases (B25%) were refractory to such therapy from the outset. The successful use of a-interferon has also been reported in four cases, with durable responses of greater than 41 and 66 months in two of these (cases 5, 15, and 35). Allogeneic sibling SCT has now been reported in five cases (ages 15, 40, 44, 49, and 60 years) of CNL in the chronic or accelerated phase or following induction chemotherapy for BT (Table 2) . Four patients remain alive, disease-free more than 6 (two patients), 4, and >1 1 2 year out from the procedure. The median survival of all 40 patients with CNL thus far reported in the literature and carefully selected by the WHO criteria was 23.5 months (range: 1-106). Causes of death included intracranial hemorrhage (n ¼ 9), progressive disease (n ¼ 5), BT (n ¼ 4), infection (n ¼ 1), and regimen-related toxicity post-transplantation (n ¼ 1) ( Table 2) .
Current management decisions in CNL are based on anecdotal reports or extrapolated from therapeutic strategies effective in similar chronic, clonal myeloid disorders. Given the potential for BT and progressive refractory neutrophilia, allogeneic SCT may be appropriate for younger patients. Continued reporting of all cases of CNL and responses to therapeutic strategies must be encouraged. We read with great interest the recent clinical score developed by Gallardo et al 1 for predicting the outcome after HLA-identical sibling donor allogeneic stem cell transplantation (SCT) in myeloid malignancies. However, we were somewhat surprised that cytogenetic variables were not taken into account as part of the analysis of SCT outcomes in acute myeloid leukemia (AML). Several studies over recent years have clearly defined cytogenetics as a major determinant of relapse risk and survival in AML, including post-SCT. 2, 3 There is now general consensus that cytogenetic risk groups be used as the basis of selecting treatment strategies in AML, including allogeneic SCT. 4, 5 In general, patients with good-risk cytogenetics are recommended for SCT only after relapse, and patients with poor-risk7inter-mediate-risk cytogenetics considered for HLA-identical sibling allogeneic SCT in first CR. Thus, we believe that analysis of SCT outcomes in AML without including cytogenetic information has limited generalised applicability.
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Using the clinical score developed by Gallardo et al, we also analysed the results of HLA-matched sibling donor allogeneic SCT performed at our institution for adult patients with AML between 1987 and 2004. Score 1 was defined as the presence of no risk factors (SCT in first complete remission (CR), age o30 years and absence of sex mismatch, defined as female donor to male recipient), score 2 as SCT in first complete remission7age 430 and/or sex mismatch, score 3 as SCT beyond first CR7age430 years or sex mismatch, and score 4 the presence of all three risk factors. Overall survival (OS) and disease-free survival (DFS) were calculated by the Kaplan and Meier method, with comparison between groups performed by the log-rank test.
In total, 116 transplants had been performed, with complete data available in 114. This included 14 cases with score 1, 46 cases with score 2, 31 cases with score 3, and 23 cases with 
